Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism by Woods-Townsend, Kathryn et al.
Am. J. Hum. Genet. 76:833–849, 2005
833
Over- and Underdosage of SOX3 Is Associated with Infundibular
Hypoplasia and Hypopituitarism
Kathryn S. Woods,1 Maria Cundall,2 James Turton,1 Karine Rizotti,4 Ameeta Mehta,1
Rodger Palmer,6 Jacqueline Wong,8 W. K. Chong,7 Mahmoud Al-Zyoud,9 Maryam El-Ali,9
Timo Otonkoski,10 Juan-Pedro Martinez-Barbera,3 Paul Q. Thomas,8 Iain C. Robinson,5
Robin Lovell-Badge,4 Karen J. Woodward,2 and Mehul T. Dattani1
1London Centre for Paediatric Endocrinology, Biochemistry, Endocrinology, and Metabolism Unit, 2Clinical and Molecular Genetics Unit, and
3Neural Development Unit, Institute of Child Health, University College London, Divisions of 4Developmental Genetics and 5Molecular
Neuroendocrinology, MRC National Institute for Medical Research, and 6North-East London Regional Cytogenetics Laboratory and
7Department of Neuroradiology, Great Ormond Street Hospital for Children NHS Trust, London; 8Murdoch Children’s Research Institute,
Royal Children’s Hospital, Melbourne; 9Department of Paediatric Endocrinology, Hamad Medical Corporation, Doha, Qatar; and 10Hospital
for Children and Adolescents, University of Helsinki, Helsinki
Duplications of Xq26-27 have been implicated in the etiology of X-linked hypopituitarism associated with mental
retardation (MR). Additionally, an expansion of a polyalanine tract (by 11 alanines) within the transcription factor
SOX3 (Xq27.1) has been reported in patients with growth hormone deficiency and variable learning difficulties.
We report a submicroscopic duplication of Xq27.1, the smallest reported to date (685.6 kb), in two siblings with
variable hypopituitarism, callosal abnormalities, anterior pituitary hypoplasia (APH), an ectopic posterior pituitary
(EPP), and an absent infundibulum. This duplication contains SOX3 and sequences corresponding to two transcripts
of unknown function; only Sox3 is expressed in the infundibulum in mice. Next, we identified a novel seven-alanine
expansion within a polyalanine tract in SOX3 in a family with panhypopituitarism in three male siblings with an
absent infundibulum, severe APH, and EPP. This mutation led to reduced transcriptional activity, with impaired
nuclear localization of the mutant protein. We also identified a novel polymorphism (A43T) in SOX3 in another
child with hypopituitarism. In contrast to findings in previous studies, there was no evidence of MR or learning
difficulties in our patients. We conclude that both over- and underdosage of SOX3 are associated with similar
phenotypes, consisting of infundibular hypoplasia and hypopituitarism but not necessarily MR.
Introduction
The pituitary gland consists of anterior, intermediate,
and posterior lobes and is a central regulator of growth,
metabolism, and development. Its complex functions are
coordinated by signals from the hypothalamus that reg-
ulate the release of six different hormones secreted by
five different cell types in the anterior pituitary. Each cell
type is defined by the hormone that is secreted: corti-
cotropes (adrenocorticotrophic hormone [ACTH]), thy-
rotropes (thyroid-stimulating hormone [TSH]), gonado-
tropes (luteinizing hormone [LH] and follicle-stimu-
lating hormone [FSH]), somatotropes (growth hormone
[GH]), and lactotropes (prolactin) (Dasen and Rosenfeld
2001). The posterior lobe consists primarily of axon-
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terminal projections from two populations of hypothal-
amic neuroendocrine neurons, and it secretes vasopressin
and oxytocin.
The origins of the anterior and posterior lobes of the
pituitary gland are embryologically distinct. Rathke’s
pouch, the primordial anterior pituitary, arises from the
oral ectoderm, whereas the posterior lobe derives from
the neural ectoderm of the diencephalon. The apposi-
tion of Rathke’s pouch and the region of the dienceph-
alon that later develops into the hypothalamus is main-
tained throughout the early stages of pituitary organo-
genesis (Takuma et al. 1998) and appears to be critical
for normal anterior pituitary development. A number
of gene products (Fgf8, Bmp4, and Nkx2.1 [Lazzaro et
al. 1991; Ericson et al. 1998; Takuma et al. 1998]) that
are expressed in the neural ectoderm but not in Rathke’s
pouch are thought to play a significant role in normal
anterior pituitary development, as illustrated by the phe-
notype of mouse mutants that are null or hypomorphic
for these alleles. These molecules are thought to activate
or repress key regulatory genes encoding transcription
factors, such as Hesx1, Lhx3, and Lhx4, within the
developing Rathke’s pouch, and these factors are es-
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sential for subsequent development of the pituitary (Ta-
kuma et al. 1998; Dasen and Rosenfeld 2001).
Failure of normal pituitary development results in con-
genital hypopituitarism, a condition that is associated
with considerable morbidity and occasional mortality if
undiagnosed or inadequately treated. Mutations within
a number of transcriptional factors have been associated
with hypopituitarism in humans, either in isolation or
combined with other manifestations, such as optic nerve
hypoplasia or a short stiff neck. These genes, mutations
of which may be inherited in an autosomal recessive
or dominant manner, include POU1F1 (MIM 173110)
(Pfaffle et al. 1992; Radovick et al. 1992), PROP1 (MIM
601538) (Wu et al. 1998), HESX1 (MIM 601802) (Dat-
tani et al. 1998), LHX3 (MIM 600577) (Netchine et al.
2000), and LHX4 (MIM 602146) (Machinis et al. 2001).
A number of pedigrees with X-linked hypopituitarism
and variable degrees of learning difficulty have recently
been described. Duplications at Xq26-27 have been de-
scribed in many of these pedigrees (Hamel et al. 1996;
Lagerstrom-Fermer et al. 1997; Hol et al. 2000; Solomon
et al. 2002), which together define a 3.9-Mb critical re-
gion between Xq26.1 and Xq27.3 (mental retardation,
X-linked, with isolated growth hormone deficiency
[MIM 300123]) (Solomon et al. 2004). This duplicated
region contains 18 annotated transcripts, including well-
characterized genes, ESTs, and predicted exon sequences.
One of these, the developmental transcriptional factor
SOX3 (MIM 313430), is a good candidate, given that
it is expressed in the developing infundibulum in mice,
and overexpression in other tissues results in a hypo-
plastic phenotype in fish (Koster et al. 2000).
SOX3 is a single-exon gene located on the X chro-
mosome in all mammals. It contains an HMG box and
is believed to be the gene from which the testis-deter-
mining gene SRY evolved. On the basis of sequence ho-
mology, SOX3 is closely related to SOX1 and SOX2
(MIM 184429), and the products of all three genes
belong to the SOXB1 subfamily and are expressed
throughout the developing CNS (Collignon et al. 1996).
The three genes encoding members of the SOXB1 family
are expressed in neuroepithelial progenitor and stem cells
from the earliest stages, and there is considerable overlap
in their expression patterns.
Recently, an in-frame duplication within SOX3 that
results in an expansion of a polyalanine (PA) tract by
11 alanine residues was described in a pedigree char-
acterized by mental retardation (MR) and short stature
due to GH deficiency (Laumonnier et al. 2002). PA ex-
pansions have been described in a number of genes as-
sociated with diverse human phenotypes (Brown and
Brown 2004). These include FOXL2 (MIM 605597)
(Crisponi et al. 2001), HOXA13 (MIM 142959)
(Goodman et al. 2000), HOXD13 (MIM 142989)
(Muragaki et al. 1996), PABPN1 (MIM 602279) (Brais
et al. 1998), RUNX2 (MIM 600211) (Otto et al. 2002),
ZIC2 (MIM 603073) (Brown et al. 2001), ARX (MIM
300382) (Bienvenu et al. 2002; Stromme et al. 2002),
and PHOX2 (MIM 603851) (Nakano et al. 2001). The
functional consequences of such expansions are unclear
and could be associated with either gain or loss of func-
tion. It has been suggested that causative alanine tract
expansions within the polyadenine-binding protein nu-
clear 1 (PABPN1) protein may lead to protein aggre-
gation, with resulting insoluble inclusions and conse-
quent cell death (Brown and Brown 2004), whereas PA
expansions within HOXD13 are associated with a shift
in localization from the nucleus to the cytoplasm, where
the mutant protein forms large amorphous aggregates
(Albrecht et al. 2004). Similar cytoplasmic mislocaliza-
tion was observed in the 11-alanine expansion in SOX3
that was reported by Laumonnier et al. (Laumonnier et
al. 2002; Albrecht et al. 2004), although the effects of
this expansion on transcription are unknown.
Together, these data suggest that the dosage of SOX3
could be critical for normal hypothalamopituitary de-
velopment and that both overdosage (by duplication) and
underdosage (by PA tract expansion) could cause hy-
popituitarism. We therefore sought additional examples
of over- and underdosage of SOX3 among patients with
hypopituitarism who were recruited from national and
international centers. We now report a submicroscopic
duplication at Xq27.1 in association with variable hy-
popituitarism in two siblings. This duplication spans
685.6 kb and is the smallest described to date, containing
only SOX3 and two other transcripts of unknown func-
tion, of which only murine Sox3 is expressed in the in-
fundibulum. These data strongly implicate SOX3 dupli-
cation as the cause of the hypopituitary phenotype. We
have also identified, in three brothers with panhypopi-
tuitarism, a novel PA expansion (from 15 to 22 alanine
residues) within SOX3. We show here that the seven-
alanine expansion is associated with loss of transcrip-
tional activation, possibly as a result of its impaired
cellular localization. We have also identified a novel
polymorphism (A43T) in SOX3 in a child with hypo-
pituitarism associated with an unusual abnormality of
the corpus callosum. In contrast to findings in previous
studies (Hamel et al. 1996; Lagerstrom-Fermer et al.
1997; Hol et al. 2000; Laumonnier et al. 2002; Solomon
et al. 2002, 2004), there was no evidence of MR or
learning difficulties in any of our patients. Both the du-
plication and the PA expansion mutations in SOX3 are
associated with anterior pituitary hypoplasia (APH), an
absent infundibulum, and an ectopic/undescended pos-
terior pituitary. Our data suggest that SOX3 expression
is critical for normal development of the hypothalamo-
pituitary axis in humans, that both over- and underdos-
age of SOX3 give rise to a similar phenotype of infun-
dibular hypoplasia and hypopituitarism, and that neither
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Table 1
Primers Used for UPQFM-PCR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
over- nor underdosage of SOX3 is obligately associated
with MR in X-linked hypopituitarism.
Material and Methods
Patient Recruitment
Patients with congenital hypothalamopituitary dis-
orders were recruited into the study from both national
and international pediatric and adult endocrinology cen-
ters from 1998 through 2004. A total of 76 male pro-
bands were screened for mutations within SOX3, and
19 were tested for a duplication by interphase FISH. Ap-
proval was obtained from the Institute of Child Health/
Great Ormond Street Hospital for Children Joint Re-
search and Ethics Committee. Prior to collection of sam-
ples and genomic analysis, informed written consent was
obtained from the parents and, where applicable, the
patients.
Clinical Evaluation
Clinical details were obtained for all patients recruited
into the study. These included birth details, perinatal
complications, history of consanguinity, family history,
and parental heights, as well as the results of standard
dynamic tests of pituitary function and magnetic reso-
nance imaging (MRI). For those patients recruited from
centers where hormonal assays were performed using
different commercial radioimmunoassay kits, normal
values for each center were taken into account for the
diagnosis of hormone deficiencies.
Interphase FISH for Detection and Characterization
of SOX3 Duplication
Nineteen individuals (14 sporadic cases and 5 familial
cases with presumed X-linked inheritance) with variable
degrees of hypopituitarism were screened for duplication
of the SOX3 locus by interphase FISH, performed using
a human genomic BAC clone (bA51C14) containing the
SOX3 gene. A control probe was hybridized on a sep-
arate slide for each individual, with the use of either
another genomic clone from Xq27 or one mapping to
Xq22. In many cases, the mother of the affected male
was also screened for the presence of possible duplica-
tions involving SOX3. FISH was performed on cultured
lymphocyte nuclei that were isolated from peripheral
blood samples by use of standard protocols. The BAC,
PAC, or cosmid clones were labeled with Spectrum
Green dUTP by nick translation, performed using a Nick
Translation kit (Vysis), and this was used in conjunction
with a Spectrum Orange–labeled X centromere probe
(Vysis). Interphase FISH was performed as described
elsewhere, and hybridization signals in 1100 nuclei were
scored for each slide (Woodward et al. 2003).
Clones around the SOX3 gene at Xq27.1 (bA197K18,
bA35F15, bA364B14, bA189F12, bA359I11, dJ595A18,
dJ177G6, and bA338I3) were selected for mapping du-
plication breakpoints. The clones, which were obtained
from the Wellcome Trust Sanger Institute, mapped be-
tween positions 137.4 Mb and 138.7 Mb on the X chro-
mosome (Ensembl Genome Browser [NCBI build 34 hu-
man genome assembly]).
Genotyping Studies
Polymorphic microsatellite markers mapping near
SOX3 (DXS1232, DXS8013, and DXS984) and else-
where on the X chromosome (DXS6807, DXS9895,
DXS6800, DXS1191, DXS8075, DXS6797, DXS8045,
DXS1212, and DXS1200) were amplified using fluo-
rescently labeled primers in a standard PCR mix. Cycling
conditions were 95C for 5 min; 30 cycles of 95C for
45 s, 55C for 30 s, and 72C for 45 s; and holding at
72C for 10 min. Completed reactions were diluted and
electrophoresed using an ABI 377 sequencer along with
a GeneScan 500 TAMRA size standard (Applied Bio-
systems) and were analyzed using Genotyper software
(Applied Biosystems).
Universal Primer Quantitative Fluorescent Multiplex
PCR (UPQFM-PCR)
UPQFM-PCR was performed using primers across the
region (see table 1); the method used for UPQFM-PCR
was based on that described by Heath et al. (2000). The
primary reaction was a standard PCR mix, in a volume
of 10 ml, modified only with respect to the concentration
of primer (1 pmol, 2 pmol, or 4 pmol of each primer).
Up to six pairs of tagged primers were used in each
reaction, including two control primer pairs: a primer
pair that amplified exon 6 of PLP1, which lies on the
X chromosome, and one from the CFTR locus on chro-
mosome 7. Cycling conditions were 95C hot start for
15 min; 10 cycles of 94C for 30 s, 56C for 45 s, and
72C for 45 s; and holding at 72C for 10 min. Sec-
ondary PCRs were performed in a total volume of 20
ml, which was seeded with 2 ml of the primary reaction
as a template; again, a standard PCR mix was used, with
20 pmol of each universal primer. Cycling conditions
were identical to the primary reaction, except that 20
cycles were used. From each completed UPQFM-PCR,
1 ml was electrophoresed on an ABI 377 automatic se-
quencer (as described above). Dosage of the sequence
amplified by each primer pair was calculated from the
ratio obtained by dividing the ratio of the fluorescent
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signal from each primer pair to that of each control
primer by the same ratio in a group of normal, sex-
matched controls.
PCR to Amplify Duplication Breakpoint Junction
Long-range PCR was performed using oligonucleotide
primers with a length generally between 25 and 30 nu-
cleotides; the primers were designed using Primer 3 to
be near the breakpoint regions mapped by FISH and
UPQFM-PCR. A 25-ml standard reaction mix with the
following modifications was used: 280 mM dNTPs, 5
ml Q solution (Qiagen), 0.5 ml (0.2 U) diluted ProofStart
enzyme (Qiagen) (2 U diluted in 9.2 ml 1# ProofStart
PCR buffer [Qiagen]), and 2.5 U HotStarTaq (Qiagen).
Cycling conditions were as follows: a 95C hot start for
15 min; 40 cycles of 95C for 15 s, 65C for 30 s, and
68C for 10 min; and elongation at 68C for 10 min.
RT-PCR
Ten micrograms of human brain RNA (6–12 wk ges-
tation [ViroGen]) were treated with 1 U DNase I (In-
vitrogen), in accordance with the manufacturers’ rec-
ommendations. One hundred pmol random nonamers
and oligo d(T) were added to 10 mg RNA, and reverse
transcription was performed using Superscript II reverse
transcriptase (Invitrogen), followed by incubation with
4 U RNase H (Invitrogen) at 37C for 30 min. PCR was
then performed under standard conditions with the use
of oligonucleotide primers specific to SOX3 (SOX3-3F
and SOX3-3R in Xiang et al. [2000]) and to the En-
sembl-annotated genes ENST00000343662 (RT-1F and
RT-1R) and 000329997 (RT-3F and RT-3R). cDNA was
also amplified using primers from the HPRENST00T
gene (HPRT-F and HPRT-R) to check for genomic DNA
contamination.
RT-PCR and in situ hybridization analysis of the ENS-
MUSG00000036258 and Sox3 genes was performed as
described elsewhere (Solomon et al. 2004). Primers for
the following genes were used: ENSMUSG00000036258
(forward: 5′-catcattcgtcgggaagacctc-3′; reverse: 5′-ccattcg-
gttacgcttgtgc-3′) and GAPDH (forward: 5′-cttgctcagtgtcc-
ttgctg-3′; reverse: 5′-acccagaagactgtggatgg-3′).
PCR and Automated Sequencing Analysis of DNA
SOX3 is a single-exon gene with a high GC content.
Various primer pairs spanning the exon were designed,
and different combinations were used for PCR (see table
1) (Xiang et al. 2000). Because of the high GC content
of the gene, modified PCR conditions were used; 1 M
betaine was included in the PCR mix. An initial dena-
turation step of 98C for 15 min was used, followed by
the addition of Taq enzyme. A standard PCR protocol
was then used: 94C for 4 min; 35 cycles of 94C for 1
min, 68C for 30 s, and 72C for 30 s; and a final ex-
tension of 72C for 10 min. PCR products were treated
with shrimp alkaline phosphatase and exonuclease I
(PCR Product Presequencing kit [Amersham Biosci-
ences]) prior to sequencing with the ABI Prism BigDye
Terminator kit, version 3.1 (Applied Biosystems). The
sequencing protocol for SOX3 was also modified; 1 M
betaine was again included in the reaction mix, and an
initial denaturation step of 98C for 15 min was used
prior to the addition of the BigDye mix (i.e., BigDye
enzyme mix plus dilution buffer) to the PCR products.
Sequencing conditions were as follows: 35 cycles of 95C
for 10 s, 62C for 20 s, and 68C for 4 min. Sequencing
of the duplication breakpoint was performed using a
standard sequencing protocol with BigDye version 3.1.
The products were directly sequenced using a MegaBace
Sequencer (Amersham Biosciences) and were analyzed
using Sequencer software (Gene Codes). The sequences
that were obtained were compared with the reference
sequence (GenBank accession number X71135).
Plasmid Constructs
Since SOX3 is a single-exon gene, it was possible to
amplify the entire gene from both unaffected (wild type)
and affected (A(7)240∧241 ins) individuals and to clone
the wild-type and mutated cDNAs for functional studies.
To generate protein for electrophoretic mobility shift as-
say (EMSA) experiments, SOX3 cDNAs (SOX3 and
SOX3(A(7)240∧241 ins)) were subcloned into the ex-
pression vector pCMV/SV-Flag, downstream of the T7
promoter. For the transfection and cell localization ex-
periments, Gal4-SOX3 fusion proteins (Gal4-SOX3 and
Gal4-SOX3(A(7)240∧241 ins)) were constructed as de-
scribed elsewhere for HESX1 (Brickman et al. 2000,
2001). A reporter construct containing SOX binding
sites within the Hesx1 promoter sequence (Eroshkin et
al. 2002), upstream of the firefly luciferase gene, was
used in the transcriptional assays. A 570-bp PCR frag-
ment upstream of the initiation ATG was cloned into
the pGL3-basic vector (Promega). Primers were 5′-ggcgg-
taccctgcgttttcattgacaacg-3′ and 5′-ggccctcgagtcttctgggtc-
gtacagcg-3′. The reporter construct containing reiterated
Gal4 binding sites upstream of the SV40 promoter has
been described elsewhere (Brickman et al. 2001).
Cell Culture and Transfections
CHO cells were cultured in Dulbecco modified Eagle
medium, supplemented with 10% fetal calf serum (FCS)
and 2 mM L-glutamine. Transient transfection assays
were performed using lipofectamine (Invitrogen), in ac-
cordance with the manufacturer’s protocol (with mod-
ifications). Transfections were performed on three sep-
arate occasions, each in triplicate.
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Table 2
Endocrine Phenotypes of Patients with SOX3 Mutation, Duplication, and Polymorphism
PEDIGREE
(NATIONALITY)
AND PATIENT
AGE AT
PRESENTATION
(years)
HEIGHT SDS
AT PRESENTATION
WEIGHT SDS
AT PRESENTATION
CONCENTRATION OF
GH
(ng/ml)
FT4
(ng/dl)
TSH
(mU/ml)
Prolactin
(ng/ml)
Peak Cortisol
(mg/dl)
Peak LH
(IU/liter)
Peak FSH
(IU/liter)
A (Finnish):
1 7.0 2.8 .9 1.0 1.0 2.8 6.2 33.7 5.0 4.5
2 .2 3.8 1.5 1.3 .6 .01 5.5 2.5 .8 .5
B (Qatari):
1 3.0 2.5 NA 1.7 .5 .08 NA 2.0 U U
2 4.5 2.5 NA .7 .7 3.3 7.3 3.9 .5 .5
3 2.7 1.3 .7 .7 .5 2.8 NA 3.2 1 !1
C (Ghanaian):
1 0 NA .9 2.2 .7 4.7 34.8 1.8 1.1 .6
NOTE.—NA p not available; U p undetectable. Normal ranges: peak GH 16.7 ng/ml, FT4 0.9–1.9 ng/dl, TSH 0.5–6.0 mU/ml, peak cortisol
119.8 mg/dl, and prolactin 5–25 ng/ml.
Cell Localization Studies
Cells ( ) were seeded into each chamber4np 2# 10
of a four-chamber tissue culture plate. The DNA con-
centration of the transfected Gal4-SOX3 plasmids var-
ied as indicated in the figure legends, but the total
amount of DNA transfected per well was normalized to
200 ng by adding the appropriate amount of empty ex-
pression vector. Cells were incubated with transfection
media (DNA  OptiMem) for ∼15 h and then were
refed with normal growth media. Cells were fixed 36 h
after transfection in 4% paraformaldehyde. After fixa-
tion of the cells, slides were blocked with 10% FCS and
then were incubated with an a-Gal4 antibody (Santa
Cruz [1:250]) or anti-chick SOX3 antibody (1:500) (a
gift from T. Edlund) for 1 h. The slides were washed
and incubated with an a-rabbit secondary antibody (Al-
exa 488 donkey a-rabbit [Molecular Probes]) (1:1,000)
for 1 h. Nuclear counterstaining was performed with
Vectashield containing 4′,6-diamidino-2-phenylindole di-
hydrochloride (DAPI) (Vector Laboratories). Immuno-
staining was then visualized on a Zeiss Axioskop 2 Plus
microscope, and images were captured using a Zeiss Ax-
iocam camera.
Dual Luciferase Transfection Experiments
In brief, cells were seeded into each well of51# 10
a 12-well plate 24 h prior to transfection with 75 ng of
pRL-SV40 Renilla luciferase vector (Promega), to con-
trol for transfection efficiency, and 100 ng of the ap-
propriate firefly luciferase reporter. The DNA concen-
trations of the other transfected plasmids varied as
indicated in the figure legends, but the total amount of
transfected DNA was normalized to 1.2 mg by addition
of the appropriate amount of empty expression vector.
Cells were incubated with transfection media (DNA 
OptiMem) for ∼15 h and then were refed with normal
growth media. Cells were collected 24 h later and as-
sayed for luciferase activity following the Dual Lucif-
erase protocol (Promega).
Purification of Recombinant Proteins and Gel Shift
Assays
SOX3 proteins were expressed using the TNT Quick
Coupled Transcription/Translation System (Promega).
EMSAs were performed as described elsewhere (Brick-
man et al. 1999, 2000), with the use of a consensus bind-
ing sequence for SOX proteins present in the mouse
Hesx1 promoter region (Eroshkin et al. 2002) and equiv-
alent amounts of in vitro translated protein. The SOX3
probe was obtained by annealing the primers 5′-agctcaaa-
caaataaacaattaactc-3′ and 5′-gtcagagttaattgtttatttgtttg-3′
(italics represent the SOX binding sequence). The an-
nealed probe was radioactively labeled using Ready-To-
Go DNA Labeling Beads (dCTP) (Amersham Biosci-
ences) with 32P dCTP (Amersham Biosciences).
Results
Family A: Overdosage of SOX3
Patient 1.—The first patient presented at age 7 years
with a height of 107.6 cm (2.8 SD score [SDS]), weight
of 20.5 kg (0.9 SDS), and history of hypoglycemia and
hyponatremia at birth. The midparental height was 179
cm (0.2 SDS), with a maternal height of 168 cm (0.7
SDS). A diagnosis of GH insufficiency was made on the
basis of combined insulin/arginine provocation testing
(table 2), and the patient was treated with recombinant
human GH (rhGH). His FT4 concentrations have ranged
from 0.5 ng/dl to 1.0 ng/dl, with normal FT3 concen-
trations, a basal serum TSH concentration of 2.8 mU/
ml, and a peak TSH concentration of 13.9 mU/ml in
response to TRH. The variable FT4 concentrations to
date may indicate the possibility of evolving TSH defi-
ciency. His serum prolactin and cortisol concentrations
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Figure 1 Family A, MRI scans in patients with SOX3 dupli-
cation. Coronal and sagittal MRI scans of patient 1 (panel a) and
patient 2 (panel b) from family A, showing APH (“AP”), partial hy-
poplasia of the infundibulum (“I”) in patient 1 (absent in patient 2),
and an undescended/ectopic posterior pituitary (“PP”) (partial in pa-
tient 1). Note the cyst in the corpus callosum identified in patient 1.
Family B, MRI scans in patients with PA expansion in SOX3. Coronal
and sagittal MRI scans of patient 2 (panel a) and patient 3 (panel b)
from family B, showing APH (“AP”), hypoplasia of the infundibulum
(“I”), and an undescended/ectopic posterior pituitary (“PP”).
were normal. He progressed through puberty sponta-
neously. His current height is 171 cm (0.7 SDS) at age
17 years. MRI revealed a hypoplastic anterior pituitary,
with hypoplasia of the lower half of the infundibulum
and a partially descended posterior pituitary at the tip
of the infundibulum. A cyst was noted within the splen-
ium of the corpus callosum, and the septum pellucidum
was normal (fig. 1 [family A, panel a]). His psychomotor
development is normal.
Patient 2.—The half brother of patient 1 presented at
age 2 mo (height 54.2 cm [3.8 SDS]; weight 5.1 kg
[1.5 SDS]) with a history of neonatal hypoglycemia
and was found to have severe cortisol, TSH, GH, and
gonadotrophin deficiency (table 2). He had hypoplastic
genitalia, with both testes palpable high in the inguinal
canal and a micropenis. He was treated with thyroxine,
rhGH, and hydrocortisone. He is currently 2.5 years old,
with a height of 94 cm (0.6 SDS) and weight of 14.5
kg (0.4 SDS). MRI revealed hypoplasia of the anterior
pituitary, absence of the infundibulum, and an ectopic/
undescended posterior pituitary. The corpus callosum
was normal (fig. 1 [family A, panel b]). He has normal
psychomotor development but has been noted to be
hyperactive.
Family B: Underdosage of SOX3
Patient 1.—Patient 1 is currently 17 years old. He was
born to first-degree consanguineous Qatari parents, and
he first presented with short stature (height 83 cm [2.5
SDS]) at age 3 years. His heterozygous mother is of
normal height. General examination revealed two small
testes lying in the scrotum. He had elevated fasting tri-
glycerides, and clonidine and L-dopa stimulation re-
vealed low peak GH concentrations (peak GH 1.7 ng/
ml and 1.9 ng/ml, respectively) (table 2). The patient
showed an excellent response to treatment with rhGH,
with a height velocity increasing from 4 cm/year pre-
GH to 11 cm/year with rhGH treatment. A CT scan was
reported as being normal. A trial period of suspended
rhGH treatment was associated with a marked reduction
in the patient’s height velocity to 1 cm/year. rhGH treat-
ment was therefore recommenced. Although the initial
total thyroxine concentration was normal, repeat inves-
tigations at age 6.2 years confirmed secondary TSH de-
ficiency (free T4 0.5 ng/dl; TSH 0.08 mU/ml). At age 15
years, he was noted to be prepubertal, with small testes
and undetectable concentrations of LH and FSH. Treat-
ment with a depot preparation of testosterone (Susta-
non) was therefore commenced. The patient also com-
plained of weakness and was found to have a stimulated
serum cortisol concentration of 2.0 mg/dl, confirming
ACTH deficiency. Hydrocortisone treatment was there-
fore commenced. He is currently being treated with Sus-
tanon, rhGH, thyroxine, and hydrocortisone. His cur-
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rent height is 162.5 cm (1.9 SDS), and his weight is
66.5 kg (0.2 SDS). His neurodevelopment is normal.
Patient 2.—Patient 2 is currently 15 years old. He pre-
sented at age 4.5 years with a height SDS of 2.5 and a
poor growth velocity of 4 cm/year. He had a micropenis,
with bilaterally undescended testes. Investigations (in-
cluding a clonidine provocation test) at age 6 years re-
vealed GH deficiency (peak GH 0.7 ng/ml; IGF-1 unde-
tectable), cortisol deficiency (peak cortisol on provocation
3.9 mg/dl), hypothyroidism (FT4 0.7 ng/dl; basal TSH 3.3
mU/ml; peak TSH in response to TRH provocation 24.8
mU/ml [120 min]), and a normal serum prolactin concen-
tration (7.3 ng/ml) (table 2). A 3-mo course of Sustanon
led to an increase in the size of the phallus. MRI identified
a severely attenuated anterior pituitary gland in the sella
turcica, a hypoplastic infundibulum, and an undescen-
ded/ectopic posterior pituitary at the level of the third
ventricle. The rest of the intracranial structures, includ-
ing the optic pathways, were normal (fig. 1 [family B,
panel a]). Treatment with rhGH, hydrocortisone, and
thyroxine was commenced. Puberty was induced with
Sustanon at age 13.5 years, when the basal and peak
serum gonadotrophins following LH-releasing hormone
stimulation were !0.5 IU/liter. He has normal neuro-
development to date, with good school progress. His
current height is 159 cm (1.2 SDS), and his weight is
61.4 kg (0.6 SDS).
Patient 3.—Patient 3 is currently 13 years old. He was
first seen at age 2.7 years, with short stature (height 88.5
cm [1.3 SDS]; weight 15.2 kg [0.7 SDS]), micropenis,
and undescended testes. Investigations revealed a free
T4 concentration of 0.5 ng/dl (normal 0.6–1.9), TSH
concentration of 2.8 mU/ml, LH concentration of 1.0 IU/
liter, FSH concentration of !1.0 IU/liter, and a low IGF-
1 concentration (table 2). Treatment with thyroxine was
commenced. Subsequent clonidine provocation testing
revealed a peak GH concentration of 0.7 ng/dl, with a
stimulated cortisol concentration of 3.2 mg/dl. rhGH and
hydrocortisone replacement was commenced. Although
the testes descended into the scrotum in response to 3
wk of human chorionic gonadotrophin, the testosterone
response was poor (from !0.1 ng/ml to 0.6 ng/ml). His
height SDS and weight SDS are currently0.1 and1.5,
respectively. Pubertal induction was required, and the
patient is currently also receiving Sustanon. MRI re-
vealed a small anterior pituitary gland in a small pitu-
itary fossa. The infundibulum was difficult to visualize,
since it was severely attenuated, with an ectopic/unde-
scended posterior pituitary (fig. 1 [family B, panel b]).
Another male sibling presented at age 9 years with
deficiencies of GH (peak GH 2.8 ng/ml on clonidine
provocation) and, possibly, gonadotrophin (basal and
peak serum LH and FSH !0.5 IU/liter). He has normal
serum thyroxine (free T4 1.0 ng/dl), prolactin (8.7 ng/
ml), and basal cortisol (12.1 mg/dl) concentrations. Cur-
rently, he is 12.5 years old, with a height of 138 cm
(1.8 SDS) and weight of 59.8 kg (1.9 SDS). MRI
revealed APH, an absent infundibulum, and an unde-
scended/ectopic posterior pituitary gland. DNA from
this child is unavailable.
Overdosage of SOX3
Identification of a novel SOX3 duplication.—A dupli-
cation including SOX3 was found in one family from
Finland, with two half brothers affected with differing
degrees of hypopituitarism (fig. 2a, 2b, 2e, and 2g). Their
mother is a carrier of the duplication (fig. 2c) and is
phenotypically unaffected, with a height of 168 cm; the
maternal grandmother does not carry the duplication
(fig. 2d).
Characterization of duplication.—The size of the du-
plication was mapped using genomic clones mapping
close to SOX3 (fig. 2e). This mapped the extent of the
duplication proximal to SOX3 to between two adjacent
genomic clones, ∼500 kb distant from SOX3, and the
distal end of the duplication mapped within a clone ad-
jacent to bA51C14. Refinement of the location of the
two duplication breakpoints was performed by UPQFM-
PCR, with the use of unique tagged primer pairs close
to the breakpoint regions, as mapped by interphase FISH
(fig. 2e). We have deduced the size of the duplication
from the position of the breakpoints, under the as-
sumption that there are no further deletions/duplications
associated with the rearrangement. Long-range PCR am-
plification across the breakpoint junction was performed
using oligonucleotide primers designed within the break-
point regions, because dual-color interphase FISH, per-
formed using two probes within the duplication, indi-
cated a tandem head-to-tail rearrangement (data not
shown). One primer pair combination (35F15R71430
and 595a18F114741), with each oligonucleotide map-
ping to one end of the duplicated region, amplified a 4–
5 kb product from genomic DNA from the members of
the family known to carry the duplication, confirming
that the duplication rearrangement was in tandem. No
amplification was observed with this combination of
primers in DNA from normal individuals or the grand-
mother, who did not carry the duplication.
The use of primers 595A18F116286 and 35F15R-
68658 to sequence the breakpoint in both directions
from genomic DNA from one of the affected males re-
vealed no homology between the two sequences at either
end of the duplication. Four nucleotides (CTCA) were
inserted at the breakpoint, consistent with a duplication
mechanism involving nonhomologous end joining (Lie-
ber et al. 2003) (fig. 2f). The breakpoint at the proximal
end of the duplication was located within an AluJb re-
peat from genomic clone bA35F15, and the distal break-
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Figure 2 Duplication of SOX3 in family A. a–d, Representative interphase nuclei from four members of the family (older sibling [a],
younger half brother [b], mother [c], and maternal grandmother [d]), with bA51C14 shown in green and the X centromere shown in red. e,
Data used to map the extent of the duplication. Clones from the SOX3 genomic region are shown along with position (in Mb) on the X
chromosome (NCBI build 34 assembly of the human genome). The clones duplicated by interphase FISH are blackened, those not duplicated
are shaded light gray, and the clone containing the breakpoint is shaded dark gray; unknown duplication status is indicated by the unblackened
area. The positions of genes within the duplicated region are designated by blackened boxes above the scale bar. The positions of UPQFM-
PCR primer pairs are designated by vertical arrows above the contig. Two plus signs underneath a primer pair indicate that dosage quotients
for this primer pair were consistent with a duplication; one plus sign shows that this region had a normal copy number. The position of the
informative polymorphic marker, DXS984, is also shown. f, Electropherogram showing sequence from the duplication breakpoint in family A.
The four nucleotides not present in either the proximal or the distal normal sequence are boxed above the electropherogram. Underneath, a
ClustalW alignment of the normal distal (bA595A18), normal proximal (bA35F15), and junction sequence is shown, demonstrating that there
is no homology at the proximal and distal ends of the duplication. g, Pedigree of family A. h, RT-PCR for the three genes within the duplication,
performed using human brain mRNA at 6, 7, 8, 9, 10, and 12 wk of gestation. Genomic DNA was included as a positive control. Transcripts
were present for SOX3 and a novel gene (Ensembl ENST00000343662). The larger 1,721-bp product was not amplified from the brain RNA,
showing that there was no genomic DNA contamination. i, RT-PCR analysis for ENSMUSG00000036258 (murine homologue of
ENSG00000343662), showing expression in the mouse embryo at 14.5 days postcoitum (dpc). Expression was not detected in the hypothalamic/
pituitary region, the pituitary progenitor cell line aT1-1, or the adult pituitary. No amplification was evident in the RT controls, indicating
that the cDNA was not contaminated with genomic DNA. Lane 1, 14.5–dpc embryo RT; lane 2, 14.5-dpc embryo RT; lane 3, 14.5-dpc
hypothalamus/pituitary RT; lane 4, 14.5-dpc hypothalamus/pituitary RT; lane 5, aT1-1 RT; lane 6, aT1-1 RT; lane 7, adult pituitary
RT; lane 8, adult pituitaryRT; lane 9, genomic DNA as template; lane 10, water as a blank. j, In situ analysis of the ENSMUSG00000036258
and Sox3 genes in the developing murine hypothalamus, infundibulum, and pituitary. No expression of ENSMUSG00000036258 was detected
(left panel). Sox3 is expressed in the infundibulum (arrow) and ventral diencephalon but not in the presumptive anterior pituitary (middle
panel). No staining was observed using the Sox3 sense control probe (right panel). INF p infundibulum; VD p ventral diencephalon; ALp
anterior lobe.
point was within a unique sequence in genomic clone
bA595A18.
The tandem duplication in this family is the smallest
described to date (685.6 kb in length). Microsatellite
markers on the X chromosome were genotyped to de-
termine the origin of the duplication in the family. Three
microsatellites mapping within the duplicated region
were typed, but only one, DXS984 (fig. 2e), was infor-
mative. Both affected males shared the same allele at this
locus, which was inherited from the maternal grand-
father (data not shown). No skewing of X inactivation
was observed (using a method that is based on differ-
ential methylation of HpaII restriction sites near a poly-
morphic CAG repeat in the androgen receptor gene) in
DNA extracted from peripheral blood obtained from the
mother, who carried the duplication (data not shown)
(Allen et al. 1992).
Expression studies suggest that SOX3 duplication is
associated with an infundibular phenotype.—The ex-
pression of the three genes mapping within the dupli-
cated interval (SOX3 and two Ensembl-predicted genes,
ENST00000343662 and ENSG00000329997) was in-
vestigated by RT-PCR. SOX3 and ENST00000343662
(a novel coding sequence predicted to contain a proline-
rich domain) could be amplified from total human fe-
tal brain RNA (6–12 wk gestation [fig. 2h]). Howev-
er, with the use of E14.5 murine infundibulum, Sox3—
but no ENSG00000343662-related product (ENSMUS-
G00000036258)—could be amplified (fig. 2i). The third
predicted human transcript, ENST00000329997, was
not amplified from human fetal brain (fig. 2h). This tran-
script contains a putative RNA-binding domain with
homology to the heterogeneous nuclear ribonucleo-
protein family, but it has no murine orthologue, and its
biological role remains unclear. Given the above data,
and given that murine Sox3 is expressed within the
infundibulum whereas ENSMUSG00000036258 is not
(fig. 2j), we suggest that the phenotype in the patients
with the 685.6-kb duplication is most likely due to ov-
erdosage of SOX3.
Underdosage of SOX3
Identification of a novel PA expansion in SOX3.—We
next investigated the role of possible loss of SOX3 func-
tion by screening for mutations in SOX3 in a cohort of
76 patients with variable hypopituitarism. Thirteen cases
were assigned as familial (more than one case in each
family), whereas 63 cases were assigned as sporadic. The
coding region, as well as 145 bp upstream and 121 bp
downstream, was sequenced. An expansion by seven al-
anines of the first PA tract was identified in a consan-
guineous family (family B) with four affected males
(A(7)240∧241 ins), with the insertion occurring between
nucleotides 720 and 721 (the A of the ATG is designated
“1”) (fig. 3a and 3b). The mother of these four children
was heterozygous for this mutation and did not exhibit
significantly skewed X inactivation in DNA extracted
from peripheral blood, as observed in family A (data
not shown).
SOX3 Polymorphism
We identified a novel missense change (c.127 GrA
[p.A43T]) in a child originally from Ghana, with spo-
842 Am. J. Hum. Genet. 76:833–849, 2005
Figure 3 a, Protein and genomic sequence showing a PA expansion within SOX3. PA expansion (from 15 to 22 alanine residues) in three
brothers (top three electropherograms) born to a consanguineous union (family B), compared with the normal wild-type sequence (bottom
electropherogram). b, Family tree of a pedigree with a mutation (A(7)240∧241 ins) within SOX3.
radic combined pituitary hormone deficiency (CPHD)
(tables 2 and 3). Although this change was not identified
in 92 white controls (46 male and 46 female) or in 72
other patients with hypopituitarism, it was identified in
a heterozygous state in 3 of 19 normal controls from an
Afro-Caribbean background. We therefore conclude that
this change is in fact a common Afro-Caribbean poly-
morphism. A polymorphism was also identified within
the first PA tract, as has been described elsewhere (732
ArC) (Raverot et al. 2004). We identified no further
changes and found no other expansions in the first PA
tract in an additional 72 male patients with hypopitui-
tarism. Previous data have shown no mutations within
SOX3 in 56 patients with idiopathic oligo-/azoospermia
and infertility (Raverot et al. 2004); 15 patients with X-
linked MR and two Australian families with hypopi-
tuitarism (Laumonnier et al. 2002); 8 patients with
46,XX sex reversal and 25 patients with 46,XY gonadal
dysgenesis (Lim et al. 2000); and 10 patients with X-
linked Rett syndrome (Xiang et al. 2000). Additionally,
Laumonnier et al. (2002) sequenced the PA tract in ques-
tion in 600 normal chromosomes and found no changes.
The Novel PA Expansion within SOX3(A(7)240∧241
ins) Is Associated with Loss of Function
Reporter assays.—To characterize the properties of
wild-type and mutant SOX3 proteins, we used the firefly
luciferase gene downstream of the proximal promoter
of Hesx1 to make a reporter construct, since this gene
Woods et al.: SOX3 Dosage in Hypopituitarism 843
Table 3
Summary of Neuroradiological Findings in Patients with SOX3 Mutations, Duplications, and Polymorphisms
PEDIGREE
(NATIONALITY)
AND PATIENT
NEURORADIOLOGICAL FINDING IN
Anterior Pituitary Posterior Pituitary Infundibulum Corpus Callosum Septum Pellucidum
A (Finnish):
1 Hypoplastic Partially descended Partial hypoplasia Cyst Normal
2 Hypoplastic Undescended Absent Normal Normal
B (Qatari):
1 NA NA NA NA NA
2 Hypoplastic Undescended Hypoplastic Normal Normal
3 Hypoplastic Undescended Hypoplastic Normal Normal
C (Ghanaian):
1 Hypoplastic Undescended Absent Hypoplastic Normal
NOTE.—NA p not available.
contains purported binding sites for SOX proteins. In
figure 4a, increasing amounts of wild-type SOX3 acti-
vated the Hesx1 reporter up to 6-fold in a dose-depen-
dent manner. With the mutated SOX3 construct, the
maximal activation achieved was 3-fold, suggesting that
expansion of the PA tract reduced the efficacy of SOX3
in this assay.
This result could be due to the inability of the protein
to bind to DNA, or it could be due to an alteration in
some other function of the protein (e.g., nuclear lo-
calization). To test this, Gal4-SOX3 constructs were
cotransfected with a reporter construct containing re-
iterated Gal4 binding sites (upstream activation se-
quence [UAS]) upstream of an SV40 promoter driving
a luciferase reporter. As shown in figure 4b, the loss of
activation of the firefly luciferase gene observed with
the mutant SOX3 construct did not appear to reflect
direct DNA binding—a finding that supports data from
EMSAs that use a consensus binding site for SOX3 (fig.
4c). On the other hand, the p.A43T missense sequence
variant identified in family C activated transcription and
bound to DNA in a manner that was similar to wild-
type SOX3 (data not shown), supporting the hypothesis
that this change reflects a polymorphic variant.
Cell localization.—Given the hypothesis that nucleo-
cytoplasmic shuttling plays a key role in the function of
SOX proteins (Smith and Koopman 2004), we studied
the cellular localization of wild-type and mutant SOX3
proteins. First, fusion proteins, with enhanced green
fluorescent protein (EGFP) added N- or C-terminal to
wild-type or mutant SOX3, were expressed in Chinese
hamster ovary (CHO) cells. These showed fluorescence
evenly distributed throughout the cell, regardless of the
position of the EGFP, with both constructs over a wide
range of plasmid concentrations (data not shown).
However, since addition of EGFP could itself cause
mislocalization of SOX3 proteins, the experiments were
repeated using the wild-type and mutant SOX3/GAL4
fusion constructs, and the transfected, fixed cells were
immunostained with antibodies to SOX3 or to the Gal4
DNA-binding domain (fig. 4d). These results showed a
distinct difference in cellular localization between the
wild-type and mutant SOX3 proteins. Wild-type SOX3/
Gal4 was predominantly localized to the nucleus of the
cell, as would be expected of a transcription factor, al-
though some protein is also present in the cytoplasm. The
mutant SOX3/Gal4 protein was largely excluded from
the nucleus, although some residual staining was found
within the nucleus.
Discussion
Congenital pituitary hormone deficiencies occur in ∼1 in
4,000 births. Of these, isolated GH deficiency is the com-
monest phenotype, followed by CPHD and septo-optic
dysplasia. To date, a number of genetic abnormalitieshave
been described in association with these disorders (Dat-
tani and Robinson 2000; Cohen and Radovick 2002). X-
linked hypopituitarism is a rare and variable condition.
Recent studies have implicated duplications at Xq26-
27 in the etiology of this form of hypopituitarism. Sol-
omon et al. (2004) recently narrowed the critical region
to a 3.9-Mb interval at Xq27 that contains 18 annotat-
ed transcripts. We have now refined the critical interval
to a 685.6-kb region in a pedigree in which two half
brothers manifest evidence of hypopituitarism. Within
this region are three transcripts: SOX3 and two other
transcripts. ENST0000032997 is not expressed in hu-
man fetal brain and does not have a murine homo-
logue. ENSG00000343662 is expressed in the human
fetal brain, but the murine orthologue (ENSMUSG-
00000036258) is not expressed in the infundibulum. On
the other hand, murine Sox3 is expressed in the infun-
dibulum (Solomon et al. 2004). Hence, our data support
the notion that SOX3 duplication is implicated in the
etiology of X-linked hypopituitarism. The first child (pa-
tient 1, family A) manifested GH deficiency, with bor-
derline low FT4 concentrations, whereas the second
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Figure 4 a, Impaired activation of Gal4-SOX3(A(7)240∧241 ins) (labeled “SOX3 (22 ala)”) at SOX binding sites. Increasing concentrations
of Gal4-SOX3 (labeled “SOX3 (15 ala)”) and Gal4-SOX3(A(7)240∧241 ins) (10 ng, 100 ng, 500 ng, and 1,000 ng) were cotransfected with
the HESX1 promoter (Hesx1-PP) luciferase reporter. Gal4-SOX3 led to a dose-dependent activation of the HESX1 promoter (a 6-fold activation
at the highest concentration tested), whereas Gal4-SOX3(A(7)240∧241 ins) was associated with impaired activation (a 3-fold activation at the
highest concentration tested). b, Impaired activation of Gal4-SOX3(A(7)240∧241 ins) (labeled “SOX3 (22 ala)”) at the SV40 promoter. Increasing
concentrations of Gal4-SOX3 (labeled “SOX3 (15 ala)”) and Gal4-SOX3(A(7)240∧241 ins) (10 ng, 100 ng, 500 ng, and 1,000 ng) were
cotransfected with the SV40 promoter reporter construct. Gal4-SOX3 led to a dose-dependent activation of the SV40 promoter (a 3.3-fold
activation at the highest concentration tested), whereas Gal4-SOX3(A(7)240∧241 ins) was associated with impaired activation (a 2-fold activation
at the highest concentration tested). a and b, One asterisk (*) indicates , two asterisks (**) indicate , and three asterisks (***)P ! .05 P ! .001
indicate . The results represent the means of three independent experiments, each performed in triplicate. c, Gal4-SOX3(A(7)240∧241P ! .0001
ins) (labeled “SOX3 (22 ala)”) binds to SOX binding sites in a manner that is similar to that of wild-type SOX3 (labeled “SOX3 (15 ala)”).
Identical amounts of in vitro translated wild-type SOX3 or SOX3(A(7)240∧241 ins) (10 ml) were added to the consensus SOX DNA-binding
site (lanes 2 and 4). Duplicate experiments—but with the addition of 15 pmol of cold probe, showing specific loss of DNA binding—are shown
in lanes 3 and 5. Lane 1 shows the effect of free probe in the absence of protein. Western blot analysis showed equivalent expression levels of
the constructs (data not shown). d, Impaired nuclear localization in Gal4-SOX3(A(7)240∧241) (labeled “SOX3 (22 ala)”). CHO cells were
transfected with 50 ng of the respective plasmid construct, as indicated. Nuclei in the cells were counterstained with DAPI. Panels i–vi, wild-
type SOX3 (labeled “SOX3 (15 ala)”), using either a-GAL4 (panels i–iii) or a-cSOX3 (panels iv–vi) antibodies; panels vii–xii, Gal4-
SOX3(A(7)240∧241) (labeled “SOX3 (22 ala)”), using either a-GAL4 (panels vii–ix) or a-cSOX3 (panels x–xii) antibodies.
sibling (patient 2, family A) manifested a more severe
CPHD phenotype. In keeping with the more severe phe-
notype in patient 2, the infundibulum was absent in this
sibling, whereas that of his half brother, patient 1, was
present but was hypoplastic in the distal portion. How-
ever, the corpus callosum in patient 1 was abnormal,
whereas that in the second sibling was normal, suggesting
that SOX3 is variably implicated in the development of
the midline forebrain structures. This variability in phe-
notype between the two half brothers may reflect differ-
ences in genetic background from their different fathers.
Their mother, who is a carrier of the duplication, did not
manifest an abnormal phenotype. The allele on which the
duplication is present was inherited from the maternal
grandfather, suggesting either that the duplication was
inherited from him, in which case he would have been
expected to have an abnormal phenotype, or that it arose
de novo in the mother. There was no evidence of skewed
X inactivation in DNA extracted from peripheral blood
in the mother, but, given that SOX3 is not expressed in
lymphocytes, these data are not surprising and do not
exclude the possibility of locally skewed X inactivation
(e.g., within the brain and infundibulum).
We have also identified, in three brothers from a con-
sanguineous pedigree, a novel PA expansion within
SOX3 that increases the size of a PA tract from 15 to
22 alanine residues. The phenotype was similar in all
three siblings with profound and complete panhypopi-
tuitarism in association with APH, an absent or hypo-
plastic infundibulum, and an ectopic/undescended pos-
terior pituitary. A fourth sibling had GH and possible
gonadotrophin deficiencies, but with similar neurora-
diological findings. Although DNA was unavailable for
genetic testing, it is highly likely that this fourth child
also harbored the PA expansion in SOX3. The similarity
in phenotype may reflect the relative genetic homogeneity
of the consanguineous union of their parents.
We have shown that SOX3 can act as an activator
of transcription and that the PA expansion was func-
tionally associated with impairment—but not complete
loss—of transcriptional activation in this assay. The PA
expansion did not appear to affect DNA binding but
did lead to impairment of nuclear localization. Thus,
the residual transcriptional activity and, hence, partial
loss of function might potentially be explained by the
presence of some residual SOX3 protein within the nu-
cleus. Our data suggesting that the PA expansion is
associated with loss, rather than gain, of function are
consistent with those of Albrecht et al. (2004), who have
recently shown that PA expansions within Hoxd13 that
are associated with synpolydactyly result in a shift in
the localization of Hoxd13 from the nucleus to the cy-
toplasm, where it forms large amorphous aggregates.
They suggested that this cytoplasmic aggregation is in-
fluenced by the length of the repeat, the level of ex-
pression, and the efficacy of degradation by the proteo-
some. Similar findings have recently been obtained for
the previously published PA expansion within SOX3,
which resulted in the expansion of the same alanine tract
from 15 to 26 alanine residues (Albrecht et al. 2004).
The longer PA expansion in this pedigree (Laumonnier
et al. 2002) appears to be associated with a more severe
phenotype, in that the affected members of the family
manifested MR and mild craniofacial abnormalities, in
addition to GH deficiency. In contrast, in the present
study, the pituitary phenotype is more severe in patients
with the shorter PA tract, and none of our patients man-
ifested evidence of MR or learning difficulties. Hence,
the relationship between the length of the PA tract and
the phenotype remains far from clear, and the brain and
infundibulum could be differentially affected, reflect-
ing differences in the relative contributions of the three
SOXB1 genes in the two tissues.
The most significant conclusion we draw from these
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studies is that the gene dosage of SOX3 appears to be
critical for the normal development of the diencephalon
and the infundibulum in humans, since both overdosage
and underdosage of SOX3 are associated with some-
what similar phenotypes. The phenotype is predomi-
nantly that of infundibular hypoplasia with variable ef-
fects on the corpus callosum. As SOX3 is not expressed
in Rathke’s pouch or in the developing anterior pituitary
(Collignon et al. 1996; Solomon et al. 2004), the re-
sulting APH is probably secondary, confirming the im-
portance of inductive mechanisms from the hypothal-
amus and infundibulum on normal anterior pituitary
development. An ectopic/undescended posterior pitui-
tary may well directly reflect the effects of infundibular
hypoplasia. A similar phenotype has previously been
observed in connection with mutations within HESX1
and LHX4, both of which are associated with APH and
an ectopic/undescended posterior pituitary (Machinis et
al. 2001; Thomas et al. 2001).
These data are consistent with observations in mice,
in which Sox3 is expressed throughout the CNS but
particularly in the ventral diencephalon and infundib-
ulum (Rizzoti et al. 2004; Solomon et al. 2004). Mice
with Sox3 deletions are affected with variable reduc-
tions in growth rate and in pituitary concentrations of
GH, TSH, LH, and FSH, in mice that survived to adult-
hood. Also, as observed in some of the human patients
with the longer PA expansion, 50% of the mutant mice
displayed craniofacial defects (Rizzoti et al. 2004). Sox3
was shown to be required at different levels for the
development and function of the hypothalamopituitary
axis; indeed, Sox3 is first necessary in the infundibulum,
for correct morphogenesis of Rathke’s pouch, and it is
also necessary, later, in the hypothalamus, for normal
hypothalamopituitary function (Rizzoti et al. 2004).
More precisely, in heterozygous female embryos in
which one copy of Sox3 had been deleted and replaced
with green fluorescent protein, which was expressed un-
der the control of the Sox3 promoter, Sox3 null cells,
in which the wild-type copy has been X inactivated,
were shown to be clustered in the infundibulum/hy-
pothalamic region. Within this cluster, cell proliferation
was reduced, showing a specific requirement for Sox3
in this region. Moreover, the infundibulum was less
evaginated, and expression of secreted factors within
this territory was expanded, probably explaining the
bifurcations that were observed in the pouch and that
persist in the adult gland as extra clefts. However, since
heterozygous female mice displayed dysmorphic glands
but were not affected with hypopituitarism, it is very
likely that the hypothalamus, where Sox3 expression is
maintained, is also affected in the Sox3 null animals.
The null mutants also showed dysgenesis of the corpus
callosum and failure of the dorsal hippocampal com-
missure to cross the midline. A similarly variable phe-
notype was reported in connection with an independent
Sox3-targeted mutation in mice (Weiss et al. 2003).
The similarity between the null mutant mice and the
pedigrees with the PA expansion and duplication de-
scribed in the present study encourage us in the notion
that the PA expansion reflects a loss of function. Given
the similarity in phenotype, we cannot rule out the pos-
sibility that the duplication could also represent a loss of
functional SOX3. It will be interesting to know whether
overexpression of Sox3 in mice generates a phenotype
that is similar to that of Sox3 null mice.
None of the patients in the present study manifested
craniofacial defects or any evidence of MR, in contrast
to findings in previous reports (Laumonnier et al. 2002).
Given that the PA expansion observed in our patients
may represent only a partial loss of function and that
the duplication reported in the present study is the
smallest reported to date, there may indeed be some
correlation between the genotype and phenotype, but
further studies are required to explore this possibility.
Similar dosage dependence has also been suggested in
patients with mutations and duplications encompassing
PAX6 (MIM 607108), SOX9 (MIM 608160), WNT4
(MIM 603490), and DAX1 (MIM 300473) (Huang et
al. 1999; Jordan et al. 2001; Hanson 2003; Meeks et
al. 2003; Vincent et al. 2003). Indeed, normal devel-
opment of the pituitary gland itself appears to be crit-
ically dependent on the timing of expression and dosage
of Hesx1 and Prop1 in the mouse (Dasen et al. 2001).
The underlying mechanism whereby both under- and
overdosage of SOX3 can lead to an abnormal pheno-
type remains unknown. Although our data are consis-
tent with those of previous studies that have suggested
that Sox3 is a transcriptional activator (Uchikawa et al.
1999), recent data have suggested that, in Xenopus lae-
vis, Sox3 can repress expression of Xnr5, a nodal-re-
lated gene that is expressed early in embryonic devel-
opment (Zhang et al. 2003). This phenomenon—where-
by a transcription factor can act as both an activator and
a repressor, in a context-dependent manner—has been
described elsewhere (Scully and Rosenfeld 2002). In this
context, target genes could be critically sensitive to dos-
age of SOX3. It is interesting that our preliminary data
suggest that the prevalence of SOX3 duplications (1/18)
and mutations (1/74) in unselected patients with hypo-
pituitarism is comparable to the prevalence of mutations
in other transcription factors, such as HESX1, but is
lower than the prevalence of mutations in the pituitary-
specific genes POU1F1 and PROP1 (J.T. and M.T.D.,
unpublished data), although the prevalence increases if
the cohort is carefully selected for familial CPHD.
In conclusion, we have shown that the dosage of
SOX3 is critical for the normal development of the in-
fundibulum and, hence, the anterior pituitary in humans.
We report the smallest duplication interval containing
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SOX3, which suggests that this candidate is the gene
most likely to be responsible for the hypopituitarism
observed in individuals with duplications of Xq26-27.
We also describe patients with a seven-alanine expan-
sion in a PA tract within SOX3 that is associated with
impaired transcriptional activity possibly consequent to
incorrect cellular localization of the protein. Two of the
patients in the present study had abnormalities of the
corpus callosum in addition to hypopituitarism, but, in
contrast to previous studies, none of our patients showed
evidence of learning difficulties or MR. This marked phe-
notypic variation should be borne in mind when consid-
ering potential X-linked GH deficiency and/or MR.
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